208 related articles for article (PubMed ID: 34640599)
1. In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.
Kim DH; Kim BG; Kim SY; Huh HJ; Lee NY; Koh WJ; Kim H; Kwon OJ; Jhun BW
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640599
[TBL] [Abstract][Full Text] [Related]
2.
Kim DH; Zo S; Kim SY; Jhun BW
Ann Lab Med; 2024 Jan; 44(1):92-96. PubMed ID: 37665290
[TBL] [Abstract][Full Text] [Related]
3. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.
Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J
Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335
[TBL] [Abstract][Full Text] [Related]
4. Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome.
Kwak N; Whang J; Yang JS; Kim TS; Kim SA; Yim JJ
Chest; 2021 Feb; 159(2):517-523. PubMed ID: 32712225
[TBL] [Abstract][Full Text] [Related]
5. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
Fujiwara K; Uesugi F; Furuuchi K; Tanaka Y; Yoshiyama T; Saotome M; Ohta K; Mitarai S; Morimoto K
Microbiol Spectr; 2021 Dec; 9(3):e0192821. PubMed ID: 34878300
[TBL] [Abstract][Full Text] [Related]
6. Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates.
Kim SY; Kim DH; Moon SM; Song JY; Huh HJ; Lee NY; Shin SJ; Koh WJ; Jhun BW
Sci Rep; 2021 Mar; 11(1):6108. PubMed ID: 33731862
[TBL] [Abstract][Full Text] [Related]
7. [In vitro Activity of Rifabutin and Clofazimine to Macrolide-Resistant Mycobacterium abscessus Complex Clinical Isolates].
Sürücüoğlu S; Özkütük N; Gazi H; Çavuşoğlu C
Mikrobiyol Bul; 2023 Oct; 57(4):639-649. PubMed ID: 37885391
[TBL] [Abstract][Full Text] [Related]
8.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL
Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Nontuberculous Mycobacteria in Nanjing and
Zhang R; Luo S; Wang N; Zhang H; Wu X
Infect Drug Resist; 2023; 16():2751-2764. PubMed ID: 37180636
[TBL] [Abstract][Full Text] [Related]
11. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial Susceptibility Testing Using the MYCO Test System and MIC Distribution of 8 Drugs against Clinical Isolates of Nontuberculous Mycobacteria from Shanghai.
Ying R; Yang J; Wu X; Yu F; Sha W
Microbiol Spectr; 2023 Feb; 11(2):e0254922. PubMed ID: 36802218
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW
Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibility of nontuberculous mycobacteria in China.
Ren W; Tan Y; Ma Z; Shang Y; Li S; Zhang X; Wang W; Yao C; Yuan J; Li L; Pang Y
BMC Infect Dis; 2024 Jan; 24(1):118. PubMed ID: 38262940
[TBL] [Abstract][Full Text] [Related]
15.
Sun Q; Liao X; Wang C; Jiang G; Yang J; Zhao J; Huang H; Wang G; Li H
J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708979
[No Abstract] [Full Text] [Related]
16. Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.
Kim KJ; Oh SH; Jeon D; Chang CL
Tuberc Respir Dis (Seoul); 2023 Jan; 86(1):47-56. PubMed ID: 36480820
[TBL] [Abstract][Full Text] [Related]
17. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
Mougari F; Loiseau J; Veziris N; Bernard C; Bercot B; Sougakoff W; Jarlier V; Raskine L; Cambau E;
J Antimicrob Chemother; 2017 Jun; 72(6):1669-1677. PubMed ID: 28333340
[TBL] [Abstract][Full Text] [Related]
19. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
20. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense.
Chu HS; Chang SC; Shen EP; Hu FR
PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
